Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) arcticnovartis
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00arcticnovartishttps://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngarcticnovartis2023-12-13 15:41:322023-12-13 15:41:32Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G) arcticnovartis
https://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.png00arcticnovartishttps://pharmastrategies.co.za/wp-content/uploads/2019/12/Pharma-Strategies-Website-Logo-300x138.pngarcticnovartis2023-12-11 08:19:032023-12-11 08:19:03Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
